10x Genomics Inc (NASDAQ: TXG) on Monday, soared 3.58% from the previous trading day, before settling in for the closing price of $15.90. Within the past 52 weeks, TXG’s price has moved between $12.95 and $57.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 35.76% annually for the last half of the decade. The company achieved an average annual earnings per share of 35.26%. With a float of $99.75 million, this company’s outstanding shares have now reached $106.98 million.
In an organization with 1259 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 65.89%, operating margin of -28.3%, and the pretax margin is -27.93%.
10x Genomics Inc (TXG) Insider Updates
Observing investor behavior towards Health Information Services industry stocks is more important than anything else. The insider ownership of 10x Genomics Inc is 17.60%, while institutional ownership is 78.77%. The most recent insider transaction that took place on Nov 22 ’24, was worth 91,612. In this transaction Chief Executive Officer of this company sold 6,693 shares at a rate of $13.69, taking the stock ownership to the 872,574 shares. Before that another transaction happened on Nov 22 ’24, when Company’s insider sold 5,807 for $13.69, making the entire transaction worth $79,485. This insider now owns 339,897 shares in total.
10x Genomics Inc (TXG) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.08 earnings per share (EPS) for the period topping the consensus outlook (set at -0.02) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.26% per share during the next fiscal year.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
10x Genomics Inc (TXG) is currently performing well based on its current performance indicators. A quick ratio of 4.12 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.25. Likewise, its price to free cash flow for the trailing twelve months is 78.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
Let’s dig in a bit further. During the last 5-days, its volume was 1.92 million. That was better than the volume of 1.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 96.55%. Additionally, its Average True Range was 0.91.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 29.81%, which indicates a significant decrease from 98.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.88% in the past 14 days, which was lower than the 84.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.91, while its 200-day Moving Average is $24.42. However, in the short run, 10x Genomics Inc’s stock first resistance to watch stands at $16.77. Second resistance stands at $17.07. The third major resistance level sits at $17.61. If the price goes on to break the first support level at $15.93, it is likely to go to the next support level at $15.39. Assuming the price breaks the second support level, the third support level stands at $15.09.
10x Genomics Inc (NASDAQ: TXG) Key Stats
Market capitalization of the company is 2.05 billion based on 121,054K outstanding shares. Right now, sales total 618,730 K and income totals -255,100 K. The company made 151,650 K in profit during its latest quarter, and -35,750 K in sales during its previous quarter.
